Primary central nervous system lymphoma

Neurologist

Volumn 6, Issue 5, 2000, Pages 245-254

  Abrey, L E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain lymphoma; Chemotherapy; Neurologic complications

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; LOMUSTINE; METHOTREXATE; METHYLPREDNISOLONE; PROCARBAZINE; THIOTEPA; VINCRISTINE;

ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIATION DOSE; SLIT LAMP; SYMPTOM; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033831503     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-200006050-00001     Document Type: Article

References (72)

1. Intracranial sarcomatous tumors of leptomeningeal origin
2. Increasing incidence of primary brain lymphoma in the US
3. Clinicopathological features, survival, and prognostic factors of primary central nervous system lymphomas:Trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographic area
4. Primary lymphoma of the central nervous system in immunocompetent patients in Southeast Scotland
5. Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996
6. Primary central nervous system lymphomas in patients with AIDS
7. Autopsy findings in the acquired immune deficiency syndrome
8. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center
9. Classification, pathogenesis and molecular pathology of primary CNS lymphomas
10. Pathogenesis and classification of primary central nervous system lymphoma: An update
11. HHV-8 DNA in CNS lymphomas from AIDS and non-AIDS patients
12. Primary central nervous system lymphomas
13. Primary malignant lymphoma of the brain: Demonstration of frequent p16 and p15 gene deletions
14. High-dose methotrexate for treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
15. Primary central nervous system lymphoma: Age and performance status are more important than treatment modality
16. Combined modality therapy for primary CNS lymphoma
17. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature
18. Primary central nervous system lymphoma: From clinical presentation to diagnosis
19. AIDS-related primary brain lymphomas: Histopathologic and immunohistochemical study or 51 cases
20. Leptomeningeal tumor in primary central nervous system lymphoma
21. Primary central nervous system lymphoma as a secondary malignancy
22. Evaluation and management of intracranial mass lesions in AIDS
23. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS
24. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography
25. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients
26. Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma
27. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma
28. Primary intracranial neoplasms in patients with HIV
29. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma
30. Adjuvant chemotherapy for primary lymphoma of the central nervous system
31. High-dose methotrexate for non-AIDS primary central nervous system lymphoma
32. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome
33. Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphoma
34. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma
35. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: A pilot study of the BOMES protocol
36. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radio-therapy: Preliminary results
37. Combination chemotherapy in primary central nervous system lymphoma (PCNSL)
38. Steroid-induced remission in CNS lymphoma
39. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: Case report and review of the literature
40. Primary CNS lymphoma: Combined treatment with chemotherapy and radiotherapy
41. Glucocorticoid treatment of primary CNS lymphoma
42. Current management of primary central nervous system lymphoma
43. Radiation therapy in non-Hodgkin lymphomas of the CNS
44. Management of primary cerebral lymphoma with initial chemotherapy: Preliminary results and comparison with patients treated with radiotherapy alone
45. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma
46. Primary malignant lymphoma of the central nervous system
47. Non-Hodgkin's lymphoma of the brain: Can high-dose, large-volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315
48. Long-term survival in primary CNS lymphoma
49. Primary central nervous system lymphoma
50. Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?
51. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group Protocol 88-06
52. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma
53. Reticulum cell sarcoma of the brain
54. Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy
55. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS
56. AIDS-related central nervous system lymphomas
57. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS
58. Management of primary central nervous system lymphoma for the patient with acquired immunodeficiency syndrome
59. Long term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy
60. Treatment of intraocular lymphoma with high-dose Ara-C
61. Chemotherapy in the management of intraocular lymphoma
62. The clinical spectrum of ocular lymphoma
63. Combination treatment of intraocular lymphoma
64. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma
65. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients
66. Relapse and late neurotoxicity in primary central nervous system lymphoma
67. Radiation-induced dementia in patients cured of brain metastases
68. Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy
69. Hydrocephalus in radiation leukoencephalopathy: Results of ventriculoperitoneal shunting
70. Progressive deterioration of intellect and motor function occurring several decades after cranial irradiation
71. Irradiation induced atherosclerosis: A factor in therapeutic planning